32.03Open32.03Pre Close0 Volume104 Open Interest210.00Strike Price0.00Turnover52.83%IV3.31%PremiumJan 17, 2025Expiry Date24.28Intrinsic Value100Multiplier12DDays to Expiry7.75Extrinsic Value100Contract SizeAmericanOptions Type0.8829Delta0.0086Gamma9.03Leverage Ratio-0.2018Theta0.0612Rho7.97Eff Leverage0.0847Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet